Back HIV/AIDS

HIV / AIDS

IAS 2015: WHO Urges More HIV Testing Outside Clinical Settings, Targeting Those Who Need It Most

In addition to recommending that routine HIV testing in medical settings be expanded to reach new groups, the World Health Organization’s new guidance on HIV testing also recommends the delivery of testing by non-medical 'lay providers," often in community settings. The guidance urges planners to make careful, strategic choices about which HIV testing interventions will be best able to reach individuals with undiagnosed HIV. New approaches may be needed to reach key populations.

alt

IAS 2015: Presumptive Treatment of TB in Advanced HIV No Better than ART and Isoniazid

Giving treatment for tuberculosis (TB) to all people with very advanced HIV disease at the time they start antiretroviral therapy (ART), before a laboratory diagnosis of TB -- so-called empiric treatment -- does not reduce the risk of death compared to giving ART and isoniazid preventive therapy, according to findings presented by Mina Hosseinipour at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

IAS 2015: No HIV Infections from Partners with Fully Suppressed Virus in Landmark Trial

Final follow up of the HPTN 052 study of treatment as prevention shows no evidence of HIV transmission from people with fully suppressed viral load to their partners, 4 years after the first results from thestudy demonstrated that early HIV treatment reduced the risk of HIV transmission by 96%, according to a report by Professor Myron Cohen at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

IAS 2015: HIV Cure Research: The Next Year [VIDEO]

Sharon Lewin from the University of Melbourne offered a brief preview of what HIV functional cure and remission research might look like in the coming year, during an HIV cure press conference at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention this week in Vancouver.

alt

IAS 2015: Opioid Substitution Therapy Combined with HIV Treatment Saves More Lives

Providing opioid substitution therapy (OST) along with antiretroviral therapy (ART) to people who inject drugs results in a significantly greater reduction in deaths compared to providing either intervention alone, according to a study by Bohdan Nosyk and colleagues from the University of British Columbia Centre of Excellence in HIV/AIDS at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver. Research from Ukraine, also presented at the conference, showed that people receiving opioid substitution therapy had better engagement with HIV care.

alt

IAS 2015: New NNRTI Doravirine Suppresses HIV as Well as Efavirenz But with Fewer CNS Side Effects

Merck's next-generation NNRTI doravirine (formerly known as MK-1439) was found to be as effective as efavirenz at suppressing HIV replication, but half as many study participants taking doravirine experienced drug-related adverse events -- in particular central nervous system (CNS) side effects -- and were less likely to stop treatment prematurely, according to study findings reported this week at the at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention this week in Vancouver.

alt

IAS 2015: Young Woman Stays Undetectable for 12 Years Off Treatment After Early HIV Therapy

The 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) heard on Monday of a case of a young woman who was infected with HIV at birth and received very early antiretroviral therapy as a child, and has stayed off therapy since the age of 6 with a viral load well below the detectability limit of standard tests. Such "post-treatment controllers" are models for a "functional cure," which is one of the goals of HIV treatment research.

alt